Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer
Open Access
Abstract
No abstract availableKeywords
Funding Information
- ESMO
This publication has 28 references indexed in Scilit:
- Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancerOncotarget, 2017
- The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer PatientsInternational Journal of Gynecological Cancer, 2017
- ESMO-Magnitude of Clinical Benefit Scale version 1.1Annals of Oncology, 2017
- Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or PeritoneumJournal of Clinical Oncology, 2017
- Long-Term Ovarian Cancer Survival Associated With Mutation in BRCA1 or BRCA2JNCI: Journal of the National Cancer Institute, 2013
- Adjuvant Chemotherapy for Stage I Clear Cell Carcinoma of the OvaryInternational Journal of Gynecological Cancer, 2012
- Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III TrialJournal of Clinical Oncology, 2011
- Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trialAnnals of Oncology, 2010
- Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group studyGynecologic Oncology, 2006
- Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant RecipientsClinical Infectious Diseases, 2001